LOW DOSE COLONIC CLEANSING SYSTEM
A method of colonic cleansing that includes administering orally a first dose and a second dose of a liquid osmotic colonic evacuant composition. The second dose includes an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose.
This application claims the benefit of U.S. Provisional Application No. 60/822,703 entitled “Flavored Colonic Cleansing System” filed Aug. 17, 2006, which is incorporated by reference in its entirety.
BACKGROUNDAqueous solutions of sodium phosphate salts (monobasic and dibasic sodium phosphate), such as FLEET® PHOSPHO-SODA®, are very effective oral cathartics and are extensively used prior to colonoscopy, radiographic procedures, and surgery. For pre-colonoscopy use, a split regimen is preferred that includes one 45 mL dose given the evening before colonoscopy and a second 45 mL dose given at least three hours prior to the procedure on the following morning. Each 45 mL dose contains 21.6 g monobasic sodium phosphate, and 8.1 g dibasic sodium phosphate. Patients are instructed to consume only a clear liquids diet for the meal proceeding the first dose, and to drink large amounts of clear liquids, including water and oral rehydration solutions, for example 3 to 4 liters, after each dose. See, for example, US Published Patent Application publication no. US20040192614 to Vanner et al.
SUMMARYIn a first aspect, the invention is a method of colonic cleansing, comprising administering orally a first dose of a liquid osmotic colonic evacuant composition; and administering orally a second dose of the liquid osmotic colonic evacuant composition. The second dose comprises an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose of the liquid osmotic colonic evacuant composition.
In a second aspect, the invention is a kit for colonic cleansing, comprising a first dose of an osmotic colonic evacuant composition; and a second dose of the osmotic colonic evacuant composition. The second dose comprises an amount of the osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose of the osmotic colonic evacuant composition. The osmotic colonic evacuant is not in the form of tablets or capsules.
In a third aspect, the invention is a kit for colonic cleansing, comprising an osmotic colonic evacuant composition; and at least one dosage container. The at least one dosage container has markings to denote a first dose and a second dose, and the second dose comprises an amount that is 55% to 95% of the amount of the first dose.
In a fourth aspect, the invention is a method of colonic cleansing with a low dose colonic cleansing system, comprising administering orally 45 mL of an osmotic colonic evacuant composition; and administering orally 30 mL of the osmotic colonic evacuant composition. The low dose colonic cleansing system comprises 0.45 gram/mL of monobasic sodium phosphate and 0.18 gram/mL of dibasic sodium phosphate when solubilized in water, at least one packet comprising a flavorant, and at least one dosage container.
Because a hypertonic solution of sodium phosphate salts acts as an osmotic colonic evacuant of limited duration, it was previously thought that the administration of two equivalent doses of the salt cathartic solution was necessary to promote effective colonic cleansing. The present invention is drawn to the unexpected and surprising finding of effective phosphate salt-based colonic cleansing systems that employ a second dosage amount smaller than required previously.
The present invention makes use of the discovery of effective colonic cleansing systems when administered in dosages lower than that required in the past. In particular, the present invention makes use of the unexpected and surprising finding that colonic cleansing can be accomplished that is sufficient for colonoscopy by using a smaller dose colonic cleansing system that includes two doses of an osmotic colonic evacuant, where the second dose is reduced. Thus, the invention described herein achieves effective colonic cleansing using a smaller dose of osmotic colonic evacuant than previous colonic cleansing systems.
The phrase “osmotic colonic evacuant,” as used herein, refers to any composition that induces water infusion and retention into the intestinal lumen when the composition is administered to a subject. Compositions of an osmotic colonic evacuant include solids, powders, gels, or liquids. A liquid composition of an osmotic colonic evacuant may be constituted from a solid, powder, or gel composition using a physiologically acceptable carrier (e.g., water). A liquid composition of an osmotic colonic evacuant suitable for administration also may be constituted from liquid concentrate form using a physiologically acceptable carrier (e.g., water) as diluent.
The term “cathartic,” as used herein, refers to any composition that acts as a colonic evacuant for cleaning the bowels effective for colonoscopy.
The chemical composition of an osmotic colonic evacuant may be a phosphate-based cathartic, for example, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium biphosphate, sodium acid pyrophosphate, or mixtures thereof; or a sulfate-based cathartic, for example, sodium picosulfate and sodium sulfate, or mixtures thereof; or magnesium-based cathartic, for example, magnesium citrate, magnesium hydroxide, magnesium sulfate, magnesium oxide, or mixtures thereof; or magnesium sulfate (Epsom salts). Preferred osmotic colonic evacuants include magnesium sulfate or a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate. In one embodiment, the preferred osmotic colonic evacuant is the commercially available phosphate salt cathartic FLEET® PHOSPHO-SODA® (C.B. Fleet, Lynchburg, Va.; National Formulary Monograph USP 23/NF18, p. 1430), which includes sodium dihydrogen phosphate, monohydrate (NaH2PO4.H2O) (monobasic sodium phosphate) and disodium hydrogen phosphate, heptahydrate (Na2HPO4.H2O) (dibasic sodium phosphate) in water. A 45 mL dose contains 21.6 g monobasic sodium phosphate, and 8.1 g dibasic sodium phosphate.
As the first dose of the two dose treatment, preferably 15 to 25 g monobasic sodium phosphate is orally administered, for example 20 to 23 g monobasic sodium phosphate, including 21.6 g. The first dose also preferably contains 5.5 to 9.4 g dibasic sodium phosphate, for example 7.5 to 8.6 g dibasic sodium phosphate, including 8.1 g dibasic sodium phosphate.
As the second dose of the two dose treatment, preferably 55 to 95% of the first dose is orally administered, and is always less than the first dose. For example, 60 to 90% of the first dose may be used, including 60 to 70 or 80% of the first dose, such as 66%. For example, if the first dose is (i) 15 g, (ii) 20 g, (iii) 21.6 g, (iv) 23 g or (v) 25 g monobasic sodium phosphate, then the second dose could correspond to the following amounts of monobasic sodium phosphate: (i) 8.25 g to 14.25 g, including 9.0 g, 9.9 g, 10.5 g, 12.0 g and 13.5 g; (ii) 11.0 g to 19.0 g, including 12.0 g, 13.2 g, 14.0 g, 16.0 g and 18.0 g; (iii) 11.88 g to 20.52 g, including 12.96 g, 14.26 g, 15.12 g, 17.28 g and 19.44 g; (iv) 12.65 g to 21.85 g, including 13.8 g, 15.18 g, 16.1 g, 18.4 g and 20.7 g; or (v) 13.75 g to 23.75 g, including 15.0 g, 16.5 g, 17.5 g, 20.0 g, and 22.5 g. Also as an example, if the first dose contains (i) 5.5 g, (ii) 7.5 g, (iii) 8.1 g, (iv) 8.6 g or (v) 9.4 g dibasic sodium phosphate, then the second dose could correspond to the following amounts of dibasic sodium phosphate: (i) 3.02 g to 5.22 g, including 3.3 g, 3.63 g, 3.85 g, 4.4 g and 4.95 g; (ii) 4.12 g to 7.12 g, including 4.5 g, 4.95 g, 5.25 g, 6.00 g and 6.75 g; (iii) 4.45 g to 7.70 g, including 4.86 g, 5.35 g, 5.67 g, 6.48 g and 7.29 g; (iv) 4.73 g to 8.17 g, including 5.16 g, 5.68 g, 6.02 g, 6.88 g and 7.74 g; or (v) 5.17 g to 8.93 g, including 5.64 g, 6.20 g, 6.58 g, 7.52 g and 8.46 g.
Preferred phosphate salt cathartics include from 0.05 to 1.5 gram/mL of monobasic sodium phosphate and from 0.02 to 0.6 gram/mL of dibasic sodium phosphate. More preferably, the osmotic colonic evacuants of the phosphate salt cathartic variety may also include from 0.25 to 1 or from 0.4 to 1 gram/mL of monobasic sodium phosphate and from 0.1 to 0.4 or from 0.13 to 0.25 gram/mL of dibasic sodium phosphate. At present, an especially preferred phosphate salt cathartic includes about 0.48 g/mL of monobasic sodium phosphate and about 0.18 g/mL of dibasic sodium phosphate. Phosphate salt cathartics that include one phosphate salt, such as dibasic sodium phosphate, also may be used. Preferred phosphate salt cathartics have a pH from about 4.4 to about 5.2 and may be produced in multiple ways, such as by combining phosphoric acid with dibasic sodium phosphate or with caustic soda. Osmotic colonic evacuants of this type are very stable, thus having a long shelf-life, and are considered to work in a mild and very effective manner.
The colonic cleansing system may include an osmotic colonic evacuant in solid or powder form that is constituted with a physiologically acceptable carrier (e.g., water) immediately prior to administration. Optionally, the physiologically acceptable carrier may be packaged with the colonic cleansing system. The consumer may provide the source of the physiologically acceptable carrier apart from the colonic cleansing system. An example of a physiologically acceptable carrier includes sterile water. The kit will include instructions that direct the consumer about the types of physiologically acceptable carrier that may be used to constitute the osmotic colonic evacuant powder in liquid form, as well as the inclusion of any additional materials (e.g., contents of any flavor packets). Preferably, the osmotic colonic evacuant is not in the form of tablets or capsules.
In another embodiment, the colonic cleansing system may include an osmotic colonic evacuant pre-dissolved in a physiologically acceptable carrier (e.g., water). The osmotic colonic evacuant may be packaged as a total dosage form or as individual unit dosage forms (for example, a first dosage and a separately packaged second dosage). In one embodiment, the osmotic colonic evacuant is packaged as a total dosage form that is subsequently dispensed as individual unit dosage forms (a first dosage and a second dosage) using one or more dosage containers that may be included in the colonic cleansing system. The dosage container may include markings on their surfaces to denote volume fill levels appropriate for consumption of a give volume or amount of the osmotic colonic evacuant. In another preferred embodiment, the osmotic colonic evacuant is packaged as individual, ready-to-use, unit dosage forms in separate sealed containers.
Prior to consumption, flavorants and/or sweeteners may be added to the osmotic colonic evacuant to increase its palatability. Optionally, the flavorant can be present in the mixture or solution that contains the osmotic colonic evacuant. Alternatively, the flavorant and sweetener can be individually packaged apart from the osmotic colonic evacuant. The flavorant may include a citrate-based component. The citrate-based component may include citric acid, salts, such as sodium or potassium citrate, derivatives of citrate, such as a citrate derivatized with ester functionality, and the like. The flavorant also may include natural and/or artificial flavorings, such as natural and/or artificial fruit flavors, to further increase the palatability of the cathartic. Preferred sweeteners include aspartame, sucralose, and acesulfame potassium, among other ingredients. Preferably, the flavorant and sweetener may be combined as a powered mixture. Examples of such combinations include the commercially available aspartame-based drink mixture, such as the CRYSTAL LIGHT® powder that is available from Kraft Foods, Northfield, Ill. (USA) or the N&A Pink Lemonade FL System Sugar FAFT523 that is available from WILD Flavors, Inc., Erlanger, Ky. (USA). Both of these powders include aspartame, citric acid, and fruit flavors that result in flavored drinks when the powder is combined with water. Examples of compositions and uses of flavorants and sweeteners in phosphate-based cathartics are described, for example, in A
In one preferred embodiment, the flavorants and sweeteners are packaged separately from the osmotic colonic evacuant in the kit. Optionally, the flavorants and sweeteners can be pre-mixed with the osmotic colonic evacuant composition of the kit.
The colonic cleansing system also includes at least one dosage container. Preferably, at least one surface of the dosage container includes markings that denote the volume fill level to achieve a unit dose of the osmotic colonic evacuant when the dosage container is filled with the osmotic colonic evacuant. The dosage container includes markings that denote two different volume fill levels to achieve different unit doses of the osmotic colonic evacuant. A first volume fill level will be greater than a second volume fill level to produce a first unit dose having a given volume of liquid and a second unit dose having a lower given volume of liquid. More preferably, a first volume fill level will be greater than a second volume fill level to produce a ratio of first unit dose:second unit dose.
In an alternative embodiment, colonic cleansing system may include a first dosage container and a second dosage container. The two dosage containers may be substantially identical or different in form, shape, size, and volume. Preferably, the first dosage container differs from the second dosage container in only size and volume such that the second dosage container may be adapted to fit within the interior of the first dosage container. Preferably, at least one surface of each dosage container includes markings that denote the volume fill level to achieve a unit dose of the osmotic colonic evacuant when the dosage container is filled with the osmotic colonic evacuant. Preferably, the first dosage container includes at least one marking to denote a volume fill level corresponding to a first unit dose of the osmotic colonic evacuant and the second dosage container includes at least one marking to denote a volume fill level corresponding to a second unit dose of the osmotic colonic evacuant. Preferably, a first volume fill level will be greater than a second volume fill level to produce a first unit dose having a given volume of liquid and a second unit dose having a lower given volume of liquid. More preferably, a first volume fill level will be greater than a second volume fill level to produce a ratio of first unit dose:second unit dose.
Optionally, the dosage container includes an additional marking to denote the volume fill level for a physiologically acceptable carrier (e.g., water). Such a marking is useful to indicate the volume of a physiologically acceptable carrier to dissolve the contents of packets of flavorant and/or sweetener. A unit dose of the osmotic colonic evacuant may be added to the dosage container containing the dissolved flavorant and/or sweetener prior to administering the liquid composition. Examples of a dosage container include cups and spoons.
Optionally, the dosage container may contain writings, pictures, symbols or other information about the use of the dosage container for colonic cleansing or other uses, or other instructions.
The osmotic colonic evacuant may also be present as tablets or capsules. A first dosage unit may be present as one, two, three, four or more tablets or capsules, and the second dosage unit may be present as one, two, three, four or more tablets or capsules. The tablets or capsules may all be the same size or may be different sizes. The first dosage form and the second dosage form may be pre-measured and separately packaged, for example the tablets or capsules may be present in a first package for the first dose, and a separate package for the second dose.
Finally, the colonic cleansing system will include instructions directing the subject on the use of the contents of the system. For one preferred embodiment, the instructions will direct the subject to constitute an osmotic colonic evacuant powder, flavorant powder and sweetener powder into an appropriate volume of a physiologically acceptable carrier (e.g., water). The appropriate volume is at least sufficient to provide for a first unit dose and a second unit dose of a liquid osmotic colonic evacuant. The instructions may direct the subject to fill at least one dosage container with the constituted liquid osmotic colonic evacuant to a first volume fill level corresponding to a first unit dose and to consume the contents of the dosage container. The instructions may direct the subject to allow for a period of time to lapse, after which the subject is directed to fill the at least one dosage container with the constituted liquid osmotic colonic evacuant to a second volume fill level corresponding to a second unit dose and consume the contents of the dosage container. Preferably, the instructions would direct the subject to consume a first unit dose and a second unit dose of the constituted osmotic colonic evacuant where the ratio of first unit dose:second unit dose is greater than 1.00. Most preferably, the instructions would direct the subject to consume a 45 mL first unit dose and a 30 mL second unit dose of the constituted osmotic colonic evacuant comprising FLEET® PHOSPHO-SODA® (C.B. Fleet, Lynchburg, Va.; National Formulary Monograph USP 23/NF18, p. 1430), optionally supplemented with a flavorant and a sweetener.
The markings on the dosage container(s) are particularly advantageous for kits that contain a total dosage form because such markings facilitate the accurate dispensing of the appropriate volume of the osmotic colonic evacuant for consumption. In the case of kits containing individual dosage unit forms, the volume of each dosage form will be pre-determined by the fill capacity of each sealed container. Thus, the instructions of such kits need only direct the consumer to pour the contents of a given individual dosage unit form into the dosage container for consumption without reference to markings on the dosage container.
The surface of one or more dosage containers 106 may have optional markings 108 to denote volume fill levels. The containers 110 may be fitted with screw-lid tops 112 to provide an air-tight seal. The sizes of containers 110 are adapted to contain a first volume 114 and a second volume 116 of an osmotic colonic evacuant. Containers 110 include the osmotic colonic evacuant. The containers 118 and 120 may include the flavorant, sweetener and the like. The surface of one or more dosage containers 106 may include writings, pictures, symbols or other information about the use of the dosage container for colonic cleansing or other uses. The containers may take the form of bottles, tubs, sachets, envelopes, tubes, ampoules, and the like, which may be formed in part or in whole from plastic, glass, paper, foil, MYLAR®, wax, and the like. The containers may be equipped with fully or partially detachable lids that may initially be part of the containers or may be affixed to the containers by mechanical, adhesive, or other means.
By orally administering the compositions of the present invention to a subject, the colon may be cleansed. A first aliquot of the composition may be administered to the subject about 14 hours prior to the colonoscopy. This initial dose is followed by a second aliquot of the composition administered about 3 hours prior to the colonoscopy. A surprising and unexpected finding of the present invention is that effective colonic cleansing suitable for colonoscopy examination can be accomplished with consumption of a lower second dose of the osmotic colonic evacuant relative to the first dose of the osmotic colonic evacuant consumed. The subject should consume large amounts of liquids, 3 to 4 Liters for example, in addition to the composition to maintain adequate hydration. These additional liquids may include aqueous solutions that include oral re-hydration salts and/or electrolytes, such as HYDRALIFE™ and other oral re-hydration beverages.
While various embodiments of the invention have been described, it will be apparent to those of ordinary skill in the art that other embodiments and implementations are possible within the scope of the invention. Accordingly, the invention is not to be restricted except in light of the attached claims and their equivalents.
Claims
1. A method of colonic cleansing, comprising:
- administering orally a first dose of a liquid osmotic colonic evacuant composition; and
- administering orally a second dose of the liquid osmotic colonic evacuant composition,
- wherein the second dose comprises an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose of the liquid osmotic colonic evacuant composition.
2. A method of claim 1, wherein the liquid osmotic colonic evacuant composition comprises a phosphate cathartic.
3. The method of claim 2, wherein the phosphate cathartic comprises monobasic sodium phosphate and dibasic sodium phosphate.
4. The method of claim 1, wherein the second dose comprises an amount that is 60% to 80% of the amount of the first dose.
5. The method of claim 3, wherein the first dose of the phosphate cathartic comprises from 15 to 25 g monobasic sodium phosphate and from 5.5 to 9.4 g dibasic sodium phosphate.
6. The method of claim 3, wherein the first dose of the phosphate cathartic comprises 20 to 23 g monobasic sodium phosphate and 7.5 to 8.6 g dibasic sodium phosphate.
7-9. (canceled)
10. The method of claim 3, further comprising mixing the phosphate cathartic with a flavorant and a sweetener.
11. The method of claim 3, wherein the phosphate cathartic comprises a concentrate.
12. (canceled)
13. The method of claim 3, further comprising waiting at least three hours between administering the first dose and the second dose.
14. A kit for colonic cleansing, comprising:
- a first dose of an osmotic colonic evacuant composition, and
- a second dose of the osmotic colonic evacuant composition,
- wherein the second dose comprises an amount of the osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose of the osmotic colonic evacuant composition, and
- the osmotic colonic evacuant is not in the form of tablets or capsules.
15. A kit of claim 14, wherein the osmotic colonic evacuant composition comprises a phosphate cathartic.
16. The kit of claim 15, wherein the phosphate cathartic comprises monobasic sodium phosphate and dibasic sodium phosphate.
17. The kit of claim 14, wherein the second dose comprises an amount that is 60% to 80% of the amount of the first dose.
18. The kit of claim 16, wherein the first dose of the phosphate cathartic comprises from 15 to 25 g monobasic sodium phosphate and from 5.5 to 9.4 g dibasic sodium phosphate.
19. The kit of claim 16, wherein the first dose of the phosphate cathartic comprises 20 to 23 g monobasic sodium phosphate and 7.5 to 8.6 g dibasic sodium phosphate.
20-22. (canceled)
23. The kit of claim 16, wherein the first dose and the second dose of the phosphate cathartic are in a single sealed container.
24. The kit of claim 16, wherein the first dose and the second dose of the phosphate cathartic are in separate sealed containers.
25. The kit of claim 16, further comprising a flavorant and a sweetener.
26. (canceled)
27. The kit of claim 16, wherein the phosphate cathartic comprises powder.
28-31. (canceled)
32. The kit of claim 16, further comprising a dosage container.
33. (canceled)
34. A kit for colonic cleansing, comprising:
- an osmotic colonic evacuant composition; and
- at least one dosage container,
- wherein the at least one dosage container has markings to denote a first dose and a second dose, and
- the second dose comprises an amount that is 55% to 95% of the amount of the first dose.
35. The kit of claim 34, wherein osmotic colonic evacuant composition comprises a phosphate cathartic.
36. The kit of claim 34, wherein the phosphate cathartic comprises monobasic sodium phosphate and dibasic sodium phosphate.
37. The kit of claim 34, wherein the second dose comprises an amount that is 60% to 80% of the amount of the first dose.
38. The kit of claim 36, further comprising a flavorant and a sweetener.
39-42. (canceled)
Type: Application
Filed: Aug 20, 2012
Publication Date: Feb 14, 2013
Inventor: Michael L. Caswell (Lynchburg, VA)
Application Number: 13/589,859
International Classification: A61K 33/42 (20060101); B65D 85/00 (20060101); A61P 1/00 (20060101);
